{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
UroGen Pharma Ltd.
UroGen Pharma Hits Day High with 18.83% Surge in Stock Price
UroGen Pharma has seen notable stock activity, with significant gains over various time frames, including a 121.03% increase year-to-date. Despite challenges such as a negative book value and slow long-term growth, the company boasts a high return on equity of 165.96%.
UroGen Pharma Hits New 52-Week High of $23.64, Up 84.34%
UroGen Pharma has achieved a new 52-week high of USD 23.64, significantly up from its low of USD 3.42, reflecting an impressive one-year performance. With a market cap of USD 991 million, the company shows strong financial metrics but remains loss-making, indicating evolving market dynamics in the Pharmaceuticals and Biotechnology sector.
Is UroGen Pharma Ltd. technically bullish or bearish?
As of October 31, 2025, UroGen Pharma Ltd. has shifted to a bullish trend, supported by positive moving averages and Bollinger Bands, despite a mildly bearish MACD signal, and has outperformed the S&P 500 with an 86.01% year-to-date return compared to 16.30%.
Is UroGen Pharma Ltd. technically bullish or bearish?
As of October 31, 2025, UroGen Pharma Ltd. has shifted to a bullish trend, supported by positive daily moving averages and Bollinger Bands, despite mixed signals from MACD and KST, and it has outperformed the S&P 500 with a year-to-date return of 93.62% compared to 16.30%.
Is UroGen Pharma Ltd. technically bullish or bearish?
As of October 31, 2025, UroGen Pharma Ltd. is in a bullish trend, supported by strong short-term performance and positive moving averages, despite some caution from weekly indicators and underperformance over the past 3-5 years compared to the S&P 500.
Is UroGen Pharma Ltd. technically bullish or bearish?
As of October 31, 2025, UroGen Pharma Ltd. is in a bullish trend overall, supported by positive moving averages and Bollinger Bands, despite some short-term caution from the MACD and KST indicators, while it has outperformed the S&P 500 year-to-date and over the past year.
UroGen Pharma Hits Day High with 9.46% Surge in Stock Price
UroGen Pharma's stock has shown strong performance, gaining 9.46% on October 24, 2025, and achieving a 56.78% return over the past year. Despite challenges such as a negative book value and modest long-term growth, the company's market capitalization is currently USD 991 million.
UroGen Pharma Hits Day High with 15.59% Surge, Outperforming S&P 500
UroGen Pharma's stock surged significantly on September 30, 2025, reaching an intraday high and showcasing strong performance in the pharmaceuticals sector. Over the past year, the company has outperformed the S&P 500, but it faces challenges such as a negative book value and scrutiny over its debt servicing capabilities.
UroGen Pharma Ltd. Experiences Evaluation Revision Amidst Mixed Performance Indicators
UroGen Pharma Ltd. has recently revised its evaluation amid changing market conditions. The stock, priced at $17.99, has shown resilience with a 32.87% return over the past year, outperforming the S&P 500. Despite challenges in longer-term performance, the company continues to navigate the competitive biotechnology landscape.
Is UroGen Pharma Ltd. technically bullish or bearish?
As of September 19, 2025, UroGen Pharma Ltd. shows a mildly bullish technical trend, with mixed indicators across timeframes, while outperforming the S&P 500 with a year-to-date return of 68.92% compared to 13.31%.
Is UroGen Pharma Ltd. technically bullish or bearish?
As of September 19, 2025, UroGen Pharma Ltd. shows a mildly bullish technical trend with strong MACD and KST indicators, despite mixed signals from Dow Theory, and has outperformed the S&P 500 year-to-date and over one year, though it has underperformed over the last five and ten years.
Is UroGen Pharma Ltd. technically bullish or bearish?
As of July 28, 2025, UroGen Pharma Ltd. shows a bullish technical trend, supported by strong MACD and moving averages, despite a recent short-term underperformance compared to the S&P 500.
Is UroGen Pharma Ltd. overvalued or undervalued?
As of November 9, 2020, UroGen Pharma Ltd. is considered risky and overvalued due to negative valuation ratios, including a Price to Book Value of -7.31 and a P/E ratio of -6.39, despite a strong year-to-date return of 77.18%.
Is UroGen Pharma Ltd. overvalued or undervalued?
As of November 9, 2020, UroGen Pharma Ltd. is considered a risky investment with significant undervaluation and negative financial ratios, yet it has shown a remarkable 241.29% return over the past month, indicating potential for recovery despite its challenges.
Is UroGen Pharma Ltd. technically bullish or bearish?
As of June 17, 2025, UroGen Pharma Ltd. shows a neutral technical stance with mixed signals, indicating a shift from mildly bearish to sideways, as weekly indicators suggest mild bullishness while monthly indicators remain bearish.
Who are in the management team of UroGen Pharma Ltd.?
As of March 2022, UroGen Pharma Ltd.'s management team includes Dr. Arie Belldegrun (Independent Chairman), Ms. Elizabeth Barrett (President and CEO), and several Independent Directors: Ms. Cynthia Butitta, Dr. Fred Cohen, Ms. Kathryn Falberg, Dr. Stuart Holden, and Mr. Ran Nussbaum. They oversee the company's strategic direction and operations.
What does UroGen Pharma Ltd. do?
UroGen Pharma Ltd. is an Israel-based biopharmaceutical company focused on developing treatments for cancers and urologic diseases. As of March 2025, it has a market cap of $610.46 million, with net sales of $20 million and a net loss of $44 million.
How big is UroGen Pharma Ltd.?
As of Jun 18, UroGen Pharma Ltd. has a market capitalization of 610.46 million and reported net sales of 91.87 million with a net profit of -138.42 million over the latest four quarters. Shareholder's funds are at -8.80 million, and total assets amount to 285.71 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
